文献速递淋巴瘤

晚期结节性淋巴细胞为主型霍奇金淋巴瘤的组织病理学生长模式:HD18随机研究德国霍奇金研究组报告

Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
PubMed 文献 · Br J Haematol · 2021-08-15

该研究回顾性分析HD18随机研究中60例晚期结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者的组织病理学生长模式。

要点

  • 晚期NLPHL中58%(35/60)为不典型生长模式。
  • 不典型模式与IV期疾病和脾受累显著相关。
  • PET-2引导的 escalated BEACOPP 治疗后,生长模式不影响5年PFS和OS。

核心结论

  • 晚期NLPHL常伴不典型生长模式,但其预后影响被PET-2引导的escalated BEACOPP所补偿。

研究设计与样本

  • 回顾性分析随机HD18研究中的60例晚期NLPHL患者,评估组织病理学生长模式。

主要发现

  • 35/60例(58%)患者为不典型生长模式。

临床怎么用

  • 对于晚期NLPHL,组织病理学生长模式可能提示疾病范围,但治疗决策可依据PET-2引导的escalated BEACOPP方案,无需因生长模式改变治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET-2) tended to be more common (P = 0·1078). Five-year progression-free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49-1·47] and overall survival (HR = 0·85; 95% CI = 0·49-1·51) did not differ between the groups after study treatment with PET-2-guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET-2-guided escalated BEACOPP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Eichenauer DA, Bühnen I, Kreissl S, et al. Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. Br J Haematol. 2021. PMID: 34396513. doi:10.1111/bjh.17770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。